ROME Therapeutics
@rometx.bsky.social
Illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for autoimmune and neurodegenerative diseases. www.rometx.com
Such a great article by Mitch Leslie in @science.org about the potential of inhibiting LINE-1 RT – a genomic, virus-like repetitive element – to address a spectrum of diseases, including ROME’s focus: #neurodegenerative and #autoimmune diseases. www.science.org/content/arti...
#darkgenome
#darkgenome
Could blocking ‘jumping genes’ help fight disease and aging?
The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own
www.science.org
April 18, 2025 at 5:24 PM
Such a great article by Mitch Leslie in @science.org about the potential of inhibiting LINE-1 RT – a genomic, virus-like repetitive element – to address a spectrum of diseases, including ROME’s focus: #neurodegenerative and #autoimmune diseases. www.science.org/content/arti...
#darkgenome
#darkgenome
Thrilled to announce this publication – many congrats to all of the ROMANS who contributed to this landmark research & to our esteemed academic collaborators, too! Targeting LINE-1 RT may be key to addressing unmet needs for many diseases. We’re proud to be a #darkgenome & LINE-1 RT pioneer!
Rosana
Rosana
We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...
March 3, 2025 at 2:32 PM
Thrilled to announce this publication – many congrats to all of the ROMANS who contributed to this landmark research & to our esteemed academic collaborators, too! Targeting LINE-1 RT may be key to addressing unmet needs for many diseases. We’re proud to be a #darkgenome & LINE-1 RT pioneer!
Rosana
Rosana
We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...
March 3, 2025 at 12:08 PM
We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...
